PMID- 25447115
OWN - NLM
STAT- MEDLINE
DCOM- 20150227
LR  - 20151119
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 159
IP  - 2
DP  - 2015 Feb
TI  - Risk factors for geographic atrophy after intravitreal ranibizumab injections for 
      retinal angiomatous proliferation.
PG  - 285-92.e1
LID - S0002-9394(14)00700-4 [pii]
LID - 10.1016/j.ajo.2014.10.035 [doi]
AB  - PURPOSE: To describe the risk factors for the development of geographic atrophy 
      (GA) following intravitreal ranibizumab injection treatment for retinal 
      angiomatous proliferation (RAP). DESIGN: Retrospective interventional series. 
      METHODS: Forty-three eyes (38 South Korean patients) from patients being treated 
      for naive RAP with intravitreal ranibizumab injection were included in this 
      study. All patients were treated with an initial series of 3 monthly loading 
      injections, followed by further injections as required. Baseline ocular 
      characteristics and lesion features assessed using fluorescein angiography (FA), 
      indocyanine angiography (ICGA), and spectral-domain optical coherence tomography 
      (SD OCT) were evaluated as potential risk factors for GA through 2 years of 
      follow-up. RESULTS: At 2 years follow-up, GA had developed in 16 of 43 eyes 
      (37.2%). The mean number of ranibizumab injections was 7.52 +/- 2.11. Using 
      multiple logistic regression, thinning of the subfoveal choroid at baseline (odds 
      ratio [OR], 0.955; 95% confidence interval [CI], 0.929-0.982; P = .002), presence 
      of reticular pseudodrusen (OR, 1.092; 95% CI, 1.017-1.485; P = .039), and 
      presence of GA in the fellow eye at baseline (OR, 1.433; 95% CI, 1.061-1.935; P = 
      .025) were identified as significant risk factors for GA development. 
      CONCLUSIONS: GA developed in 37.2% of eyes with RAP during the 24 months 
      following intravitreal ranibizumab injections. Subfoveal choroidal thinning at 
      baseline, the presence of reticular pseudodrusen, and the presence of GA in the 
      fellow eye at baseline were associated with increased risk of GA development 
      after treatment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Cho, Han Joo
AU  - Cho HJ
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea. Electronic 
      address: chojoo@kimeye.com.
FAU - Yoo, Seul Gi
AU  - Yoo SG
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea.
FAU - Kim, Hyoung Seok
AU  - Kim HS
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea.
FAU - Kim, Jae Hui
AU  - Kim JH
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea.
FAU - Kim, Chul Gu
AU  - Kim CG
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea.
FAU - Lee, Tae Gon
AU  - Lee TG
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea.
FAU - Kim, Jong Woo
AU  - Kim JW
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University College of Medicine, Seoul, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20141105
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Coloring Agents)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - IX6J1063HV (Indocyanine Green)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*adverse effects
MH  - Antibodies, Monoclonal, Humanized/*adverse effects
MH  - Coloring Agents
MH  - Female
MH  - Fluorescein Angiography
MH  - Geographic Atrophy/*chemically induced/diagnosis
MH  - Humans
MH  - Indocyanine Green
MH  - Intravitreal Injections
MH  - Macular Degeneration/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab
MH  - Retinal Neovascularization/*drug therapy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/physiology
EDAT- 2014/12/03 06:00
MHDA- 2015/02/28 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/07/30 00:00 [received]
PHST- 2014/10/27 00:00 [revised]
PHST- 2014/10/29 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/02/28 06:00 [medline]
AID - S0002-9394(14)00700-4 [pii]
AID - 10.1016/j.ajo.2014.10.035 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2015 Feb;159(2):285-92.e1. doi: 10.1016/j.ajo.2014.10.035. Epub 
      2014 Nov 5.